MEDCLMedincellMEDCL info
$18.21info0.49%24h
Global rank11168
Market cap$522.24M
Change 7d-2.03%
YTD Performance124.38%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Medincell (MEDCL) Stock Overview

    MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

    MEDCL Stock Information

    Symbol
    MEDCL
    Address
    3 rue des FrEres LumiEreJacou, 34830France
    Founded
    -
    Trading hours
    -
    Website
    https://www.medincell.com
    Country
    🇫🇷 France
    Phone Number
    33 4 67 02 13 67

    Medincell (MEDCL) Price Chart

    -
    Value:-

    Medincell Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $18.21
    N/A
    Market Cap
    $522.24M
    N/A
    Shares Outstanding
    28.68M
    N/A
    Employees
    138.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org